Compound Evidence File
#EC-2026-0106
YK11
Filed under Oral Tablets. The bureau holds 97 laboratory returns for this compound from 30 distinct subjects. Scores below are per-subject aggregates; open a subject row for the underlying evidence.
Cross-Index
Subjects Shipping This Compound
30 SUBJECTS| Subject | Grade | Samples | Mean | Min | Max | First seen | Last seen |
|---|---|---|---|---|---|---|---|
| HomopeptideCASE #VI-2026-0760 | A | 5 | 10.0 | 9.9 | 10.0 | 24 May 2026 | 24 May 2026 |
| WuXi TIDESCASE #VI-2026-0335 | A | 5 | 10.0 | 9.9 | 10.0 | 14 Nov 2025 | 7 Jun 2026 |
| Tianjin Finder Chemical TFCCASE #VI-2026-0693 | A | 4 | 10.0 | 10.0 | 10.0 | 14 Nov 2025 | 16 Apr 2026 |
| QYAOBIOCASE #VI-2026-0861 | A | 4 | 10.0 | 9.9 | 10.0 | 15 Feb 2026 | 9 Jun 2026 |
| Kerui PeptidesCASE #VI-2026-0626 | A | 4 | 10.0 | 9.9 | 10.0 | 12 Nov 2025 | 15 May 2026 |
| Hubei JianxiangCASE #VI-2026-0048 | A | 4 | 10.0 | 9.9 | 10.0 | 17 Jan 2026 | 25 Jun 2026 |
| Chinese Peptide CompanyCASE #VI-2026-0184 | A | 4 | 10.0 | 9.9 | 10.0 | 2 Apr 2026 | 15 Jun 2026 |
| Sangon BioCASE #VI-2026-0671 | A | 3 | 10.0 | 10.0 | 10.0 | 12 Jan 2026 | 16 Jun 2026 |
| Shanghai Sigma AudleyCASE #VI-2026-0505 | A | 3 | 10.0 | 9.9 | 10.0 | 4 Apr 2026 | 6 Jul 2026 |
| Shanghai ERP BiotechnologyCASE #VI-2026-0936 | A | 2 | 10.0 | 10.0 | 10.0 | 5 Mar 2026 | 18 Apr 2026 |
| Flourishglobal PeptideCASE #VI-2026-0630 | A | 2 | 10.0 | 10.0 | 10.0 | 21 May 2026 | 6 Jun 2026 |
| JEEP PeptidesCASE #VI-2026-0457 | A | 4 | 9.9 | 9.9 | 10.0 | 22 Jan 2026 | 12 Jul 2026 |
| Mokemei BiotechnologyCASE #VI-2026-0540 | A | 4 | 9.9 | 9.9 | 10.0 | 18 Mar 2026 | 13 Jun 2026 |
| Shanghai Wibson BiotechnologyCASE #VI-2026-0379 | A | 4 | 9.9 | 9.9 | 10.0 | 11 Dec 2025 | 17 Jun 2026 |
| BachemCASE #VI-2026-0314 | A | 3 | 9.9 | 9.9 | 10.0 | 16 May 2026 | 12 Jul 2026 |
| Nantong Guangyuan Chemical GYCCASE #VI-2026-0284 | A | 7 | 9.4 | 8.4 | 10.0 | 24 May 2026 | 24 May 2026 |
| Xianhong Tong XHT PeptidesCASE #VI-2026-0997 | X | 1 | 8.6 | 8.6 | 8.6 | 13 Jun 2025 | 13 Jun 2025 |
| Wuhan Wansheng Bio (WWB)CASE #VI-2026-0594 | A | 5 | 8.5 | 7.6 | 9.1 | 24 May 2026 | 24 May 2026 |
| Shandong Aishi BiotechnologyCASE #VI-2026-0308 | X | 1 | 8.1 | 8.1 | 8.1 | 14 Jan 2025 | 14 Jan 2025 |
| Glbiochem (Shanghai)CASE #VI-2026-0704 | A | 3 | 8.0 | 7.8 | 8.3 | 23 May 2026 | 23 May 2026 |
| Qingdao Sigma Chemical QSCCASE #VI-2026-0538 | A | 2 | 7.9 | 7.4 | 8.3 | 24 May 2026 | 24 May 2026 |
| Shanghai Sigma Audley SSACASE #VI-2026-0486 | A | 7 | 7.8 | 6.2 | 10.0 | 25 May 2026 | 25 May 2026 |
| Pharma Grade PeptidesCASE #VI-2026-0208 | X | 1 | 7.7 | 7.7 | 7.7 | 25 Apr 2025 | 25 Apr 2025 |
| Alpha-GenCASE #VI-2026-0905 | X | 3 | 7.1 | 5.0 | 10.0 | 9 Jun 2025 | 26 Jan 2026 |
| Kits4lessCASE #VI-2026-0744 | X | 1 | 6.9 | 6.9 | 6.9 | 20 Jun 2025 | 20 Jun 2025 |
| Skye PeptidesCASE #VI-2026-0451 | X | 4 | 6.8 | 5.0 | 9.3 | 14 Jan 2025 | 23 May 2026 |
| LSPLCASE #VI-2026-0523 | X | 3 | 6.7 | 5.7 | 8.7 | 25 Apr 2025 | 26 Jan 2026 |
| Shanghai OuDaXin New Material Technology CenterCASE #VI-2026-0498 | X | 1 | 4.7 | 4.7 | 4.7 | 16 Mar 2025 | 16 Mar 2025 |
| Peptide GurusCASE #VI-2026-0854 | X | 2 | 4.0 | 4.0 | 4.0 | 6 May 2025 | 25 May 2026 |
| NuLife PeptidesCASE #VI-2026-0980 | X | 1 | 0.0 | 0.0 | 0.0 | 16 Mar 2025 | 16 Mar 2025 |
Open any subject to view the batch-level evidence for YK11 alone.